Risk of adverse events in treatment-resistant depression: Propensity-score-matched comparison of antidepressant augment and switch strategies

General Hospital Psychiatry

Volumn 34, Issue 2, 2012, Pages 192-200

  Hansen, Richard A ^a   Dusetzina, Stacie B ^b   Ellis, Alan R ^c   Stürmer, Til ^d   Farley, Joel F ^e   Gaynes, Bradley N ^f  

^a AUBURN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Augment; Major depression; Propensity score; Switch

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; SERTRALINE; VENLAFAXINE;

ADULT; ADVERSE OUTCOME; AGED; ANXIETY; ARTICLE; BLURRED VISION; COMBINATION CHEMOTHERAPY; CONSTIPATION; COORDINATION DISORDER; DIARRHEA; DIFFICULTY URINATING; DIZZINESS; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSURIA; ENERGY; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALAISE; MALE; MENSTRUAL IRREGULARITY; MENTAL HEALTH; MICTURITION DISORDER; MONOTHERAPY; NAUSEA; ORGASM DISORDER; PATIENT COMPLIANCE; PATIENT DECISION MAKING; POLLAKISURIA; POOR CONCENTRATION; POOR COORDINATION; POSITIONAL DIZZINESS; PRURITUS; RESTLESSNESS; SEXUAL DESIRE LOSS; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; THORAX PAIN; TINNITUS; TREMOR; TROUBLE ACHIEVING ORGASM; TROUBLE WITH ERECTION; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

EID: 84857357467     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2011.10.001     Document Type: Article

References (27)

1. Kessler R.C., Berglund P., Demler O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
2. Olfson M., Marcus S.C. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009, 66:848-856.
3. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
4. Gartlehner G., Gaynes B.N., Hansen R.A., et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008, 149:734-750.
5. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
6. Trivedi M.H., Fava M., Wisniewski S.R., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354:1243-1252.
7. Nierenberg A.A., Katz J., Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am 2007, 30:13-29.
8. Shelton R.C., Osuntokun O., Heinloth A.N., Corya S.A. Therapeutic options for treatment-resistant depression. CNS Drugs 2010, 24:131-161.
9. Milea D., Guelfucci F., Bent-Ennakhil N., Toumi M., Auray J.P. Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clinical therapeutics 2010, 32:2057-2072.
10. Hansen R.A., Gartlehner G., Lohr K.N., Gaynes B.N., Carey T.S. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005, 143:415-426.
11. Gartlehner G., Thieda P., Hansen R.A., et al. Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. Drug Saf 2008, 31:851-865.
12. Williams J.W., Mulrow C.D., Chiquette E., et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000, 132:743-756.
13. Gartlehner G., Hansen R.A., Carey T.S., et al. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol 2005, 20:59-69.
14. Schweitzer I., Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf 1998, 19:455-464.
15. Lam R.W., Wan D.D., Cohen N.L., Kennedy S.H. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002, 63:685-693.
16. Rush A.J., Trivedi M.H., Stewart J.W., et al. Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168:689-701.
17. Rush A.J., Fava M., Wisniewski S.R., et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials 2004, 25:119-142.
18. Wisniewski S.R., Fava M., Trivedi M.H., et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 2007, 164:753-760.
19. Allison P.D. Missing data 2002, Sage, Thousand Oaks (Calif).
20. Graham J.W. Missing data analysis: making it work in the real world. Annu Rev Psychol 2009, 60:549-576.
21. Brookhart M.A., Schneeweiss S., Rothman K.J., et al. Variable selection for propensity score models. Am J Epidemiol 2006, 163:1149-1156.
22. Parsons L.S. Reducing bias in propensity score matched-pair sample using greedy matching techniques 2001.
23. Papakostas G.I., Fava M., Thase M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008, 63:699-704.
24. Trivedi M.H., Rush A.J., Gaynes B.N., et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology 2007, 32:2479-2489.
25. Trivedi M.H., Daly E.J. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend 2007, 88(Suppl 2):S61-S71.
26. Hansen R.A., Moore C.G., Dusetzina S.B., et al. Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Med Decis Making 2009, 29:91-103.
27. Glynn R.J., Schneeweiss S., Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98:253-259.